Agenda

Each 1-hour session will include 5 topic modules focused on current management, emerging research and novel agents and strategies under active investigation for gynecologic cancers. Each event will employ an identical format that will include the following elements:

• Moderator Dr Neil Love and a featured participating clinical investigator
• Discussion of participating faculty treatment recommendations
• Review of available clinical research findings
• Community oncologist case presentations
• Interactive audience polling and extensive Q&A

Module 1: Anti-PD-1/PD-L1 Monotherapy for Metastatic Endometrial Cancer

Module 2: Immune Checkpoint Inhibitors in Combination with Other Systemic Therapies for Metastatic Endometrial Cancer

Module 3: Current Indications for and Future Role of Anti-PD-1/PD-L1 Antibodies in Cervical Cancer

Module 4: Investigative Approaches with Immune Checkpoint Inhibitors for Ovarian Cancer

Module 5: Other Novel Agents and Strategies in Gynecologic Cancers

Target Audience
These activities are intended for gynecologic oncologists, medical oncologists, gynecologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gynecologic cancers.

Learning Objectives

• Describe the biologic rationale for, published research data with and ongoing evaluation of immune checkpoint inhibitors in the management of ovarian cancer (OC), endometrial cancer (EC) and cervical cancer (CC), and identify patients who may be eligible for this strategy as part of a clinical research study or outside of a protocol setting.
• Recognize the importance of microsatellite instability (MSI) testing for patients with OC, EC and CC, and identify the benefits observed with anti-PD-1/PD-L1 antibodies for MSI-high (MSI-H) disease.
• Appraise the clinical research supporting the FDA approval of anti-PD-1 monotherapy for progressive PD-L1-positive metastatic CC, and counsel appropriate patients about the risks and potential benefits of this approach.
• Recall available data with anti-PD-1/PD-L1 antibodies for MSI-H and microsatellite-stable recurrent EC, and appreciate ongoing research attempting to further define the role of these agents in this disease.
• Assess the recent FDA approval of pembrolizumab in combination with lenvatinib for patients with advanced EC that is not MSI-H/mismatch repair-deficient who have experienced disease progression after systemic therapy but are not candidates for curative surgery or radiation therapy in order to optimally integrate this novel regimen into current clinical management algorithms.
• Recognize the incidence of tissue factor expression in patients with CC and other gynecologic cancers, and consider the potential role of novel agents designed to exploit this therapeutic target.
• Review the mechanisms of action, emerging efficacy data and toxicity profiles of novel targeted agents under investigation in OC, CC and EC, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Konecny has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Birrer — Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: VBL Therapeutics. Dr Coleman — Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Janssen Biotech Inc, Merck, Novocure, Roche Laboratories Inc, Takeda Oncology, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, VBL Therapeutics. Dr Monk — Consulting Agreements: Agenus Inc, Akeso Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, Gradalis Inc, ImmunoGen Inc, Iovance Biotherapeutics, Karyopharm Therapeutics, McKesson/US Oncology Network, Merck, Mersana Therapeutics, Myriad Genetic Laboratories Inc, Novocure Inc, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Sorrento Therapeutics, Tesaro, A GSK Company, VBL Therapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Tesaro, A GSK Company. Dr Oaknin — Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genmab, ImmunoGen Inc, PharmaMar, Roche Laboratories Inc, Tesaro, A GSK Company; Paid Travel: AstraZeneca Pharmaceuticals LP, PharmaMar, Roche Laboratories Inc. Dr O'Malley — Advisory Committee: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genelux, Genentech, a member of the Roche Group, GOG Foundation Inc, ImmunoGen Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Merck, Myriad Genetic Laboratories Inc, Novocure, Regeneron Pharmaceuticals Inc, Tarveda Therapeutics, Tesaro, A GSK Company; Consulting Agreements: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, ImmunoGen Inc, Novocure, Regeneron Pharmaceuticals Inc, Seagen Inc, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, GlaxoSmithKline, GOG Foundation Inc, ImmunoGen Inc, Iovance Botherapeutics Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck, New Mexico Cancer Care Alliance, Novocure, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seagen Inc, Stemcentrx, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc. Data and Safety Monitoring Board/Committee: Marker Therapeutics Inc. Dr Penson — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Care4ward (unpaid), Clovis Oncology, Curio Science, Eisai Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Mersana Therapeutics, NewLink Genetics, Nexus Group Global, Pieris Pharmaceuticals Inc, Roche Laboratories Inc, Sutro Biopharma, Syndax Pharmaceuticals Inc, Tesaro, A GSK Company, Vascular Biogenics; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Tesaro, A GSK Company, Vascular Biogenics; Data and Safety Monitoring Board/Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP. Dr Powell — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Merck, Tesaro, A GSK Company. Dr Slomovitz — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Merck, Myriad Genetic Laboratories Inc; Consulting Agreement: GOG Foundation Inc. Dr Tewari — Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Tesaro, A GSK Company; Contracted Research (Institution Only): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck, Roche Laboratories Inc, Tesaro, A GSK Company. Prof Vergote — Advisory Committee: Amgen (Europe) GmbH, AstraZeneca Belux, Carrick Therapeutics, Clovis Oncology, Debiopharm Group, Deciphera Pharmaceuticals Inc, Doctaforum Servicios Sl, F Hoffmann-La Roche Ltd, Genmab, GlaxoSmithKline, ImmunoGen Inc, MSD Belgium, OCTIMET Oncology NV, Oncoinvent AS, PharmaMar, Roche Laboratories Inc, SOTIO as, Takeda Oncology, Tesaro, A GSK Company, Verastem Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc; Contracted Research: Amgen Inc, Genmab, Oncoinvent AS, Roche Laboratories Inc; Paid Travel: Amgen Inc, AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Roche Laboratories Inc.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Commercial Support
These activities are supported by educational grants from Eisai Inc, Merck, Seagen Inc and Tesaro, A GSK Company.